, Volume 69, Issue 7, pp 833–841 | Cite as

Aliskiren/Hydrochlorothiazide Combination

In Mild to Moderate Hypertension
  • Claudine M. Baldwin
  • Greg L. Plosker
Adis Drug Profile


  • ▲ Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone.

  • ▲ In double-blind, 8-week clinical trials, aliskiren and HCTZ (as a combination of the individual components or as single-pill combinations) reduced mean sitting systolic and diastolic BP from baseline to a significantly greater extent than placebo, aliskiren monotherapy and HCTZ monotherapy. Aliskiren/HCTZ produced additional BP reductions in patients inadequately responsive to 4 weeks’ prior treatment with aliskiren or HCTZ alone.

  • ▲ Responder rates and BP control rates further demonstrated the benefits of aliskiren/HCTZ combination therapy over monotherapy with individual components in patients with mild to moderate hypertension.

  • ▲ Aliskiren plus HCTZ appeared to be effective as long-term (up to 1 year) combination treatment in an open-label trial.

  • ▲ In a 12-week placebo-controlled trial in obese patients with hypertension, BP reductions and responder and control rates were significantly greater with aliskiren/HCTZ than with HCTZ alone.

  • ▲ Aliskiren/HCTZ was generally well tolerated in clinical trials, with most adverse events being mild and transient in nature.


Amlodipine Plasma Renin Activity Aliskiren Irbesartan Little Square Mean 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Acknowledgments and Disclosures

The manuscript was reviewed by: H.R. Brunner, Department of Medicine, University of Lausanne, Lausanne, Switzerland; D.A. Sica, Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.


  1. 1.
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52PubMedCrossRefGoogle Scholar
  2. 2.
    Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007 Jan; 25(1): 217–26PubMedCrossRefGoogle Scholar
  3. 3.
    Nickenig G, Simanenkov V, Lembo G, et al. Efficacy of alis-kiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press 2008; 17 (Suppl. 2): 31–40CrossRefGoogle Scholar
  4. 4.
    Novartis. Tekturna HCT® (aliskiren and hydrochlorothiazide) tablets: prescribing information (US) [online]. Available from URL: [Accessed 2009 Mar 3]
  5. 5.
    European Medicines Agency. Rasilez HCT: summary of product characteristics [online]. Available from URL: [Accessed 2009 Mar 2]
  6. 6.
    Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67(12): 1767–92PubMedCrossRefGoogle Scholar
  7. 7.
    Fenton C, Keating GM, Scott LJ. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. Drugs 2003; 63(19): 2013–26; discussion 2027-8PubMedCrossRefGoogle Scholar
  8. 8.
    Langtry HD, McClellan KJ. Valsartan/hydrochlorothiazide. Drugs 1999 May; 57(5): 751–5; discussion 756-8PubMedCrossRefGoogle Scholar
  9. 9.
    Croxtall JD, Keating GM. Irbesartan/hydrochlorothiazide in moderate to severe hypertension. Drugs 2008; 68(10): 1465–72PubMedCrossRefGoogle Scholar
  10. 10.
    Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1–8PubMedCrossRefGoogle Scholar
  11. 11.
    Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15: 3126–33PubMedCrossRefGoogle Scholar
  12. 12.
    Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12(4): 297–303PubMedCrossRefGoogle Scholar
  13. 13.
    Pool J, Gradman A, Kolloch R, et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension [abstract no. 790]. Eur Heart J 2006 Sep; 27 Suppl.: 119. Plus poster presented at the World Congress of Cardiology; 2006 Sep 2–6; BarcelonaGoogle Scholar
  14. 14.
    Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007 May; 49(5): 1047–55PubMedCrossRefGoogle Scholar
  15. 15.
    Ayalasomayajula S, Yeh CM, Vaidyanathan S, et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolar-ization and conduction in healthy subjects. J Clin Pharmacol 2008 Jul; 48(7): 799–811PubMedCrossRefGoogle Scholar
  16. 16.
    Vaidyanathan S, Jarugula V, Dieterich HA, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008; 47(8): 515–31PubMedCrossRefGoogle Scholar
  17. 17.
    Vaidyanathan S, Limoges D, Yeh C, et al. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers [abstract no. PIII-23]. Clin Pharmacol Ther 2006; 79(2): P64CrossRefGoogle Scholar
  18. 18.
    Limoges D, Dieterich HA, Yeh CM, et al. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther 2008 May; 46(5): 252–8PubMedGoogle Scholar
  19. 19.
    Waldmeier F, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007 Aug; 35(8): 1418–28PubMedCrossRefGoogle Scholar
  20. 20.
    Dieterich H, Kemp C, Vaidyanathan S, et al. Pharmacoki-netic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers [abstract no. PI-20]. Clin Pharmacol Ther 2006 Feb; 79(2): 12CrossRefGoogle Scholar
  21. 21.
    Patel RB, Patel UR, Rogge MC, et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 1984; 73(3): 359–61PubMedCrossRefGoogle Scholar
  22. 22.
    Van Tassell BW, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother 2007 Mar; 41(3): 456–64PubMedCrossRefGoogle Scholar
  23. 23.
    Blumenstein M, Romaszko J, Calderon A, et al. Anti-hypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin 2009; 25(4): 903–10PubMedCrossRefGoogle Scholar
  24. 24.
    Gradman AH, Kolloch RE, Meyers M, et al. Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension [abstract no. P-384]. J Clin Hypertens (Greenwich) 2007 May; 9 (5 Suppl. A): 160Google Scholar
  25. 25.
    Calhoun DA, Villamil AS, Chrysant SG, et al. Anti-hypertensive efficacy of aliskiren/hydrochlorothiazide (HCT) combinations in patients with stage 2 hypertension: subgroup analysis of a randomized, double-blind, factorial trial [abstract no. P209]. Hypertension 2008 Oct; 52(4): e97. Plus poster presented at the 62nd Annual High Blood Pressure Conference; 2008 Sep 17; Atlanta (GA)Google Scholar
  26. 26.
    Prescott MF, Boye SW, Le Breton S, et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorothiazide treatment in patients with extreme obesity and hypertension [abstract no. 1014-169]. J Am Coll Cardiol 2007 Mar; 49 (9 Suppl. A): 370. Plus poster presented at the 56th Annual Scientific Session of the American College of Cardiology; 2007 Mar 24; New Orleans (LA)Google Scholar
  27. 27.
    European Medicines Agency. European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines [online]. Available from URL: [Accessed 2009 Mar 3]

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthPhiladelphiaUSA

Personalised recommendations